Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Penicillamine SCHEMBL4344 | 1.00 | — | — | |
| Penicillamine SCHEMBL4343 | 1.00 | — | — | |
| Dl-Penicillamine SCHEMBL159653 | 1.00 | ALDH1A1 (1.00) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Dl-Penicillamine SCHEMBL57527 | 1.00 | — | — | |
| Penicillamine SCHEMBL129296 | 1.00 | ALDH1A1 (1.00) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Dl-Penicillamine SCHEMBL22322162 | 1.00 | ALDH1A1 (1.00) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Penicillamine SCHEMBL10789333 | 0.97 | ALDH1A1 (0.95) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Penicillamine SCHEMBL3138111 | 0.97 | ALDH1A1 (0.95) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 | |
| Penicillamine SCHEMBL6654084 | 0.97 | — | — | |
| Penicillamine SCHEMBL7932147 | 0.97 | ALDH1A1 (0.95) | ALDH1A1PTGS1MAPTSLC7A5SLC7A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110927135-B | Method for rapidly and visually distinguishing different chiral penicillamine and racemic penicillamine in sample | 无锡市疾病预防控制中心 | 2023-12-29 | — | — | CN | claimed |
| CN-110927135-A | Method for rapidly and visually distinguishing different chiral penicillamine and racemic penicillamine in sample | 无锡市疾病预防控制中心 | 2020-03-27 | — | — | CN | claimed |
| WO-2011126882-A2 | THERAPEUTIC PEPTIDES AND THEIR DERIVATIVES AND THERAPEUTIC USES THEREOF | AMERICAN TYPE CULTURE COLLECTION (US) | 2011-10-13 | — | — | WO | claimed |
| US-20110112188-A1 | Treatment of Inflammatory Conditions | DYNAMIS THERAPEUTICS, INC. | 2011-05-12 | — | — | US | claimed |
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | DYNAMIS THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | claimed |
| US-7300666-B2 | Mixture for transdermal delivery of low and high molecular weight compounds | JRX BIOTECHNOLOGY, INC. (US) | 2007-11-27 | — | — | US | claimed |
| CN-110927135-B | Method for rapidly and visually distinguishing different chiral penicillamine and racemic penicillamine in sample | 无锡市疾病预防控制中心 | 2023-12-29 | — | — | CN | disclosed |
| CN-110927135-A | Method for rapidly and visually distinguishing different chiral penicillamine and racemic penicillamine in sample | 无锡市疾病预防控制中心 | 2020-03-27 | — | — | CN | disclosed |
| US-20150374835-A1 | LIQUID TOPICAL PHARMACEUTICAL NANO-EMULSION FORMULATIONS | JRX BIOTECHNOLOGY, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150329644-A1 | PEPTIDES USEFUL FOR MODULATING HISTONE DEMETHYLASE FUNCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-19 | — | — | US | disclosed |
| US-8114406-B2 | Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-02-14 | — | — | US | disclosed |
| WO-2011159917-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20110268736-A1 | METHOD FOR TREATING CONGENITAL MYOPATHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-11-03 | — | — | US | disclosed |
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | DYNAMIS THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010057117-A2 | TOPICAL TRANSDERMAL DRUG DELIVERY COMPOSITIONS | HELM PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-7300666-B2 | Mixture for transdermal delivery of low and high molecular weight compounds | JRX BIOTECHNOLOGY, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070021357-A1 | Treatment of inflammatory conditions | DYNAMIS THERAPEUTICS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060193901-A1 | Mixture for transdermal delivery of low and high molecular weight componds | JRX BIOTECHNOLOGY, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| WO-1999050229-A1 | FATTY ACID ANALOGS AND PRODRUGS | G.D. SEARLE & CO. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | FN3K, ROS1, FN3KRP | ALDH1A1 1848/4885PTGS1 751/4885MAPT 1555/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | ALDH1A1 3292/4885PTGS1 78/4885MAPT 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.